Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 9/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229639 | 0.83 | SRC (0.36) | SRCMEN1KMT2ANR2F2NTRK1 | |
| SCHEMBL12984829 | 0.82 | NTRK1 (0.42) | NTRK1 | |
| SCHEMBL4076506 | 0.78 | NTRK1 (0.45) | POLBNTRK1 | |
| SCHEMBL2023831 | 0.74 | ALDH1A1 (0.47) | POLBMEN1KMT2APDGFRBALDH1A1 | |
| SCHEMBL15265955 | 0.73 | SRC (0.67) | SRCMEN1KMT2ANR2F2LMNA | |
| SCHEMBL1940820 | 0.72 | PDGFRB (0.49) | POLBSRCNTRK1PDGFRBLMNA | |
| SCHEMBL6221334 | 0.71 | PDGFRB (0.48) | SRCNTRK1PDGFRB | |
| Formaldehyde SCHEMBL2020497 | 0.71 | ABCG2 (0.50) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL903214 | 0.70 | ALDH1A1 (0.52) | POLBMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3704191 | 0.67 | KMT2A (0.44) | POLBMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2519525-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | DPYD, TYMP, DHFR | POLB 146/4885SRC 833/4885MEN1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.